The Commonwealth Serum Laboratories was established in Australia in 1916.
At CSL, Corporate Responsibility is about conducting our business ethically.
We offer the broadest range of quality plasma-derived and recombinant therapies in the industry.
Seqirus opened in 2015, born from the merging of CSL's bioCSL division and the Novartis influenza vaccine business.
Innovation has been in the DNA of CSL since our beginning in 1916
Our product portfolio focuses on innovation in new products
Our interim dividend for 2020 was US$0.95 per share, up 12%.
Our exceptionally strong performance is a result of the focused execution of our strategy.
Help us deliver on our promise to save lives and protect the health of people.
Make your well-being a priority. It's important and so are you.
View our ASX announcements
Visit this page to see all of our current news releases
CSL Limited's statement on Coronavirus
Forbes Magazine named CSL among its Best Employers for Diversity 2020. The annual rankings, which measure diversity across si…
Chief Executive Officer and Managing Director Paul Perreault presented the company's overview on Monday, January 13, at 3:30 …
Unique portfolio mix of plasma, cell and gene therapy, recombinant proteins and antibody assets highlighted at Research & Dev…
CSL statement in response to media reports on case against Joseph Chiao
Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange …
Two Australian scientists have each been awarded AUD$1.25 million CSL Centenary Fellowships over five years to improve treatm…
Major landmark development will significantly increase CSL’s presence in the Parkville biomedical precinct and cement Melbour…
Dr. McKenzie will be accountable for leading CSL’s global end-to-end supply chain organization and its accompanying strategy.
Popular search terms:
Americas
Asia Pacific
Europe
